Health News - Angiomax Significantly Reduces Initial Hospital Compared To Conventional Therapy In Moderate And High- Risk Acute Coronary Syndrome Patients

Join
Login
Submit Story

Categories

View All
Consumer Health Information
   Food and Drug Safety
   Drug Research
   Medical Device Information
Health News

Angiomax Significantly Reduces Initial Hospital Compared To Conventional Therapy In Moderate And High- Risk Acute Coronary Syndrome Patients

More News	Popular Upcoming

digs

dig it

Angiomax Significantly Reduces Initial Hospital Compared To Conventional Therapy In Moderate And High- Risk Acute Coronary Syndrome Patients

submitted by information

The Medicines Company (NASDAQ: MDCO) announced that a prospective analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage StrategY) trial showed that total hospital stay costs were lowest with Angiomax monotherapy (mean difference range: $184 to $1,081, p New England Journal of

Topic: Health News

Comments (0)

Comments

Add your comment
Please Login or Signup to leave a comment